These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 12939388)

  • 1. Impact of dyslipidemia in end-stage renal disease.
    Prichard SS
    J Am Soc Nephrol; 2003 Sep; 14(9 Suppl 4):S315-20. PubMed ID: 12939388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins for treatment of dyslipidemia in chronic kidney disease.
    Shurraw S; Tonelli M
    Perit Dial Int; 2006; 26(5):523-39. PubMed ID: 16973506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.
    Pennell P; Leclercq B; Delahunty MI; Walters BA
    Clin Nephrol; 2006 Nov; 66(5):336-47. PubMed ID: 17140163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
    Marrs JC; Saseen JJ
    Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperlipidemia of chronic renal failure.
    Kaysen GA
    Blood Purif; 1994; 12(1):60-7. PubMed ID: 7986478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atherogenic lipoproteins in end-stage renal disease.
    Shoji T; Ishimura E; Inaba M; Tabata T; Nishizawa Y
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S30-3. PubMed ID: 11576918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid changes and statins in chronic renal insufficiency and dialysis.
    Wanner C; Krane V; Metzger T; Quaschning T
    J Nephrol; 2001; 14 Suppl 4():S76-80. PubMed ID: 11798151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dyslipidemia in renal failure].
    Fujioka T; Ueno T; Matsumoto T; Watanabe H
    Nihon Rinsho; 2004 Jun; 62 Suppl 6():118-23. PubMed ID: 15250280
    [No Abstract]   [Full Text] [Related]  

  • 10. Dyslipidemia and renal disease: pathogenesis and clinical consequences.
    Wanner C; Quaschning T
    Curr Opin Nephrol Hypertens; 2001 Mar; 10(2):195-201. PubMed ID: 11224694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.
    Navarro JF; Mora C; Muros M; García-Idoate G
    Nephron Clin Pract; 2003; 95(4):c128-35. PubMed ID: 14694274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing metabolic complications of peritoneal dialysis.
    Pennell P; Rojas C; Asif A; Rossini E
    Clin Nephrol; 2004 Jul; 62(1):35-43. PubMed ID: 15267011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in lipid profile by nocturnal hemodialysis in patients with end-stage renal disease.
    Bugeja AL; Chan CT
    ASAIO J; 2004; 50(4):328-31. PubMed ID: 15307542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis.
    Bossola M; Tazza L; Merki E; Giungi S; Luciani G; Miller ER; Lin EB; Tortorelli A; Tsimikas S
    Blood Purif; 2007; 25(5-6):457-65. PubMed ID: 18075247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients.
    Helal I; Smaoui W; Hamida FB; Ouniss M; Aderrahim E; Hedri H; Elyounsi F; Maiz HB; Abdallah TB; Kheder A
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):59-62. PubMed ID: 20061694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein metabolism in chronic renal insufficiency.
    Saland JM; Ginsberg HN
    Pediatr Nephrol; 2007 Aug; 22(8):1095-112. PubMed ID: 17390152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.